drugset / Trial / NCT00003125
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
RandomizedTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining vaccine therapy, sargramostim, and interleukin-2 may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy, sargramostim, and interleukin-2 in treating patients who have advanced tumors.
Timeline
- Start
- 1998-01
- Primary completion
- 2004-11
- Completion
- 2004-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALVAC-CEA vaccine | Vaccine | — | Intramuscular |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |
| Subject | vaccinia-CEA vaccine | Vaccine | — | Intravenous |